Cardiol Therapeutics Inc.
Business
Cardiol Therapeutics Inc. is a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its main products are CardiolRx™ (a pharmaceutically manufactured cannabidiol oral solution) in clinical trials for pericarditis and myocarditis and CRD-38, a subcutaneous cannabidiol formulation for heart failure in preclinical development. Key activities include clinical development programs, preclinical R&D, manufacturing scale-up, and research and licensing collaborations. Cardiol conducts multinational trials and partners with academic centers and contract manufacturers across North America, Europe, Latin America and Israel.
Summary from filing dated 2025-03-31
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-33.82M |
| Total assets | $23.62M |
| Total liabilities | $5.74M |
| Stockholders' equity | — |
| Operating cash flow | — |